15th July 2019
We held our second team Away Day at Goodenough College, London, where we spent the morning working in teams to address questions that had been proposed, and were voted on, by lab members. These included how to design the ultimate study/experiment to characterise prostate cancer evolution, different ways automisation and AI could replace or hopefully just complement us and how we could improve the way we work to maximize our output and impact without compromising team spirit? In the afternoon, we had presentations on methylation in prostate cancer and methods for integrating different types of data. We finished off the day with a BBQ and some well deserved drinks!
5th July 2019
Blanca, Clinical Research Fellow, and Daniel, Senior Research Fellow, were at UCLH for the UCL Faculty of Medical Sciences Research Open Day, which celebrates all the ground-breaking research taking place at UCL. They were on hand to discuss the ReImagine project with visitors.
23rd-26th June 2019
Five members of the team, Clinical Fellows Blanca, Emily and Francesco, as well as one of our Computational Biologists, Mahedi, and Senior Research Fellow, Marina, attended the European Association for Cancer Research Cancer Genomics Conference at Churchill College in Cambridge. An opportunity for the team to enjoy some cutting-edge science, for Emily and Marina to present preliminary work from the STRATOSPHERE Consortium, but also to spend some time with collaborators from Alex Wyatt's team from Vancouver, taking part in a time honoured Cambridge tradition: punting.
23rd June 2019
Ania, Lab Manager, and Anu, Clinical Fellow, represented the team on a ReImagine stand at the Cancer Survivors' Day at Guy's and St Thomas' NHS Foundation Trust.
15th June 2019
Anu, Clinical Research Fellow, Daniel, Senior Research Fellow and Mazlina, Research Fellow, all attended Prostate Cancer UK's 10k March for Men at the Olympic Stadium in London to thank and recognise PCUK for all the support they have given us over the years.
21st May 2019
Maria, Clinical Research Fellow, and Sharan, Research Assistant, attended the International Clinical Trials’ Day at Guy’s and St Thomas’ Foundation Trust on the ReImagine (see News from 18th October) stand, talking about the work the team will be doing on the project.
9th April 2019
The PCF-SELECT (Specific Evaluation in Liquid biopsies of Established prostate Cancer Targets) Plasma DNA Assay team, a collaboration between the Treatment Resistance team, Weill Cornell, The University of Trento, The University of British Columbia, Dana-Farber Cancer Institute, Washington University and New York-Presbyterian Hospital, met up at the Cancer Institute for an update on the project's progress. Funded in late 2016 by the Prostate Cancer Foundation, the team is developing a novel genomics sequencing test capable of identifying actionable mutations from a simple blood sample.
2nd April 2019
The PRIME team (see News from 22nd September 2018), a CRUK funded collaboration between the Treatment Resistance team and Francesca Demichelis' team at the University of Trento, met up in Trento for their first face to face project update, having kept in touch with teleconferencing previously.
After the hard work, there was pizza of course!
We look forward to bringing you updates from the team's work in the next few months and years.
25th January 2019
The team enjoyed a night out at Hammersmith Town Hall to celebrate Burns Night, in honour of the Scotland's National Poet - Robert Burns - who's birthday is 25th January.
The lab ate haggis, neeps and tatties, and took part in a Ceilidh, which is traditional Scottish Dancing. Gert even wore his kilt!
22nd November 2018
Two of the team's Clinical Research Fellows, Anu and Emily, presented their work at the Cancer Institute's Annual Conference. They also took part in the one minute flash talks. A challenging but exciting way to share their projects with a wider audience across the Institute.
18th October 2018
We are delighted to announce that we are part of the MRC funded ReIMAGINE study, which will test for the first time if MRI scans can be used for population screening to detect prostate cancer more accurately. The project will combine the underlying molecular changes in the cancer with state-of-the-art imaging. This will allow the prediction of prostate cancer status for the individual (low, medium or high risk) without recourse to biopsy. It will also allow prediction of which prostate cancers are likely to progress over time and which are not, which has largely eluded scientists so far. By doing so, men will be subject to fewer but better biopsies, improved risk stratification, appropriate treatment allocation, more benefit, less harm and more cost-effective care.
Our team will lead Work Strand 4 (WS4), which is the analysis of genomic, transcriptomic, epigenetic, immune/inflammatory data from tumour cores, blood and urine.
29th September 2018
Anjui, PhD student, Daniel and Marina, both Senior Research Fellows, welcomed CRUK supporters for lab tours during the Institute's Open Day. Anjui explained the concept and applications of liquid biopsy, Daniel talked about the group's work on single cells and Marina talked about the STRATOSPHERE project. Some participants were also able to try their hand at pipetting.
A wonderful opportunity to share our work with supporters and thank them for their hard work in fundraising.
20th September 2018
The group, alongside close collaborator Francesca Demichelis (@FrancescaBZNY) at the University of Trento, Italy, has received funding through an Accelerator Award from CRUK (Cancer Research UK) and AIRC (Associazione Italiana per la Ricerca sul Cancro) to develop novel tools to analyse liquid biopsies.
PRIME (Prostate cancer plasma Integrative multimodal evaluation) aims to maximise the amount of information that can be generated from liquid biopsies, expanding their clinical uses in molecular stratification, treatment selection, and monitoring resistance.
The project will make use of the high-quality liquid biopsies from clinical trials of advanced prostate cancer, including the UK-wide, practice-changing STAMPEDE clinical trial for men starting long-term life-prolonging hormone therapies.This gives the team access to cases representative of the whole spectrum of advanced prostate cancer, including hormone-sensitive disease and through to men who have developed treatment resistance.
14th September 2018